Boehringer starts with adalimumab biosimilar

January 16, 2012 7:42 AM

As we announced earlier, Boehringer Ingelheim, the German company would establish a new separate business for the development and commercialization of own biosimilars. 

Now, according to the information on, it seems Boehringer’s studies for biosimilars are already at a certain point.

The Phase I study of BI 695501 will be a Pharmacokinetics and Safety Study which will be conducted against Adalimumab. Adalimumab, which is marketed as Humira is one the blockbusters in rheumatoid arthritis treatment.

The arms of the study will be BI 695501 against EU version of adalimumab and the third arm will also be the US version of the same originator. You can find more information about the study from the below link:

Pharmacokinetics and Safety Study of BI 695501 in Healthy Subjects

Leave a Reply

Twitter ID
(ID only. No links or "@" symbols)

Latest News on Biosimilar News

Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?


Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!